Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01601210 · ClinicalTrials.gov registry record · Early Phase 1
Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
A Early Phase 1 study, sponsored by Perry Renshaw.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT01601210 is a Early Phase 1 study that has completed, run by Perry Renshaw. The registered enrollment target is 32 participants.
The verdict
NCT01601210, a Early Phase 1 study, has completed, sponsored by Perry Renshaw.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. The primary hypothesis is that compared to placebo, 2g, 4g, and 10g of creatine monohydrate for eight weeks will be associated with a significant increase in brain phosphocreatine (PCr) concentrations.
Interventions
- DRUG Creatine monohydrate or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01601210
The ClinicalTrials.gov registry entry for NCT01601210 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perry Renshaw, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine monohydrate or placebo is the first listed.
NCT01601210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01601210 about?
NCT01601210 is a clinical study titled "Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder". The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. The primary hypothesis is that compared to placebo, 2g, 4g, and 10g of creatine monohydrate for eight weeks will be as...
What is the current status of trial NCT01601210?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2012-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01601210?
The interventions under investigation include: Creatine monohydrate or placebo (DRUG).
Who is sponsoring clinical trial NCT01601210?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.